排序方式： 共有95条查询结果，搜索用时 18 毫秒
1.
2.
目的:探讨毫火针联合中药药膜外敷治疗轻中度痤疮患者的临床效果和安全性。方法:将100例门诊确诊为轻中度痤疮的患者随机分成两组。治疗组:50例,使用毫火针配合中药药膜外敷治疗(每周2次,8周为1个疗程);对照组:50例,仅采用毫火针治疗(每周2次,8周为1个疗程),治疗1个疗程后观察两组的治疗效果及安全性。结果:治疗组:治愈6例,显效19例,有效22例,总有效率94.0%;对照组:治愈3例,显效12例,有效25例,总有效率80.0%,两组疗效比较差异有统计学意义(P<0.05)。治疗后,治疗组患者DLQI积分为2.52±0.81,显著低于对照组,差异具有统计学意义(P<0.05);治疗后,治疗组患者的DLQI积分下降幅度显著高于对照组,差异具有统计学意义(P<0.05)。治疗期间,治疗组发生不良反应1例,发生率为2%;对照组未发现明显不良反应,差异无统计学意义(P>0.05)。结论:毫火针联合中药药膜外敷治疗轻中度痤疮安全、有效。 相似文献
3.
Michihiro Hide Takamasa Suzuki Ayaka Tanaka Hiroshi Aoki 《Allergology international》2019,68(1):59-67
Background
Rupatadine, a novel nonsedating second-generation H1-antihistamine with antiplatelet-activating factor activity, has been used in the treatment of allergic rhinitis and urticaria in European countries since 2003. However, its efficacy and safety in Japanese patients with chronic spontaneous urticaria (CSU) are unknown.Methods
We conducted a prospective, multicenter, randomized, placebo-controlled, double-blind study in adolescent and adult CSU outpatients aged 12 to < 65 years (JAPIC-CTI No. 152786). Overall, 94, 91, and 92 eligible patients orally received placebo, rupatadine 10 mg, and 20 mg once daily for 2 weeks, respectively. The primary endpoint was change from baseline to the second week of treatment in total pruritus score (TPS, sum of daytime and nighttime pruritus scores).Results
The results yielded a least squares mean TPS difference of ?1.956 between rupatadine 10 mg versus placebo, and ?2.121 between rupatadine 20 mg versus placebo (analysis of covariance, both P < 0.001). The incidence of adverse events was 8.5% for placebo, 20.9% for rupatadine 10 mg, and 17.4% for rupatadine 20 mg. Somnolence was the only adverse drug reaction to rupatadine reported in 2 or more subjects. No serious or clinically significant adverse events were observed.Conclusions
The primary and secondary efficacy endpoints consistently favored rupatadine 10 and 20 mg doses over the placebo. No noteworthy dose-related increase in the incidence of adverse drug reactions was observed. Rupatadine is safe and effective at a dose of 10 mg once daily, and can be safely increased to 20 mg once daily, as necessary. 相似文献4.
April W. Armstrong Michael P. Siegel Jerry Bagel Erin E. Boh Megan Buell Kevin D. Cooper Kristina Callis Duffin Lawrence F. Eichenfield Amit Garg Joel M. Gelfand Alice B. Gottlieb John Y.M. Koo Neil J. Korman Gerald G. Krueger Mark G. Lebwohl Craig L. Leonardi Arthur M. Mandelin M. Alan Menter Abby S. Van Voorhees 《Journal of the American Academy of Dermatology》2017,76(2):290-298
5.
Saori Masaki Ryoko Tatsukawa Miki Uryu Masakazu Takahara Masutaka Furue Chika Ohata Takekuni Nakama Ryosuke Hino Motonobu Nakamura Juichiro Nakayama Shinichi Imafuku 《The Journal of dermatology》2017,44(2):143-146
There is a range of psoriasis treatments available, from topical applications to biologic therapy, with corresponding cost variations. The efficacy of each treatment is usually evaluated by objective measures such as the Psoriasis Area and Severity Index (PASI) or subjective measures such as the Dermatology Life Quality Index (DLQI). However, the social and economic impacts of psoriasis, including cost‐effectiveness, have not been assessed in Japan. The EuroQol 5‐Dimension (EQ‐5D) is a generic instrument used worldwide to calculate quality‐adjusted life years, on which calculations of treatment cost‐effectiveness are based. We conducted a pilot study to determine the cost‐effectiveness of psoriasis treatment in Japan. We administered a questionnaire to 133 patients with psoriasis (105 men and 28 women) who visited four university hospitals in Fukuoka Prefecture. The questionnaire covered medical costs, satisfaction and willingness to pay (WTP), and we investigated the relationships between these items. PASI was evaluated by physicians. More participants indicated satisfaction with treatment in the group paying less than ¥5000/month. WTP, PASI and EQ‐5D showed little correlation. However, the DLQI and EQ‐5D showed a moderate correlation (r = 0.472). WTP seemed more dependent on participants' economic backgrounds. We found that it was difficult to reflect the PASI with the EQ‐5D. However, the DLQI may be used to estimate the cost–benefit relationship in patients with psoriasis. This is the first study to evaluate the EQ‐5D in patients with psoriasis in Japan. 相似文献
6.
目的观察川百止痒洗剂联合0.1%糠酸莫米松乳膏治疗湿疹的有效性与安全性。方法采用随机、单盲、平行对照的方法对63例湿疹患者应用川百止痒洗剂联合0.1%糠酸莫米松乳膏外用治疗,同时设立对照组64例单独外用0.1%糠酸莫米松乳膏,治疗12天后评价疗效,并进行皮肤病生活质量指数(dermatology life quality index,DLQI)问卷调查。结果试验组总有效率为87.30%,与对照组70.31%相比有统计学差异(P<0.01);DLQI总分两组均下降,但无统计学差异(P=0.8775);试验组和对照组发生局部刺激反应分别为6.3%和7.8%,无统计学差异(Fisher校正χ2检验P=1.0000)。结论川百止痒洗剂联合0.1%糠酸莫米松乳膏治疗湿疹较为有效、安全。 相似文献
7.
Jillian Frieder Dario Kivelevitch Connie Tran Fiore Saadeddine Saad 《Expert Review of Clinical Immunology》2018,14(1):1-19
Introduction: Psoriasis is a common, immune-mediated skin disease often associated with significant physical and psychosocial impairment. Antipsoriatic biologic agents offer patients unparalleled treatment potential in regard to greater skin clearance and overall improved quality of life. Evaluation of the therapeutic efficacy of biologic agents on the full psoriasis disease burden must account for their impact on both physical symptoms, as well as patient-reported, health-related quality of life (HRQoL) measurements.
Areas covered: Results from numerous clinical trials demonstrate the significant clinical efficacy of biological agents targeting tumor necrosis factor-α (TNF-α) and the interleukin (IL)-12/23 and IL-17 immune pathways. However, relatively limited data is available evaluating their full effect on quality of life outcomes. This review will discuss the most relevant and up-to-date clinical data on HRQoL measurements related to treatment with these aforementioned biologic agents.
Expert commentary: Patient-reported outcomes (i.e. Dermatology Life Quality Index) are being used with increasing frequency in clinical trials, and provide valuable information on the impact of psoriasis on numerous aspects of day-to-day living. These outcomes must also be incorporated in clinical practice, in addition to physical assessment of disease severity, treatment decisions, and therapeutic response in the psoriasis patient population. 相似文献
8.
9.
10.
Tsen-Fang Tsai Ji-Chen Ho Yi-Ju Chen Pa-Fan Hsiao Woan-Ruoh Lee Ching-Chi Chi Cheng-Che Lan Rosaline Chung-Yee Hui Yang-Chih Lin Kuo-Chia Yang Tak-Wah Wong Hamm-Ming Sheu Hsiu-Cheng Hsu Gong-Yau Chu Yu-Huei Huang 《Dermatologica Sinica》2018,36(4):190-195